Right-sided cardiac masses pose therapeutic challenges, particularly in patients at high surgical risk. The AlphaVac mechanical aspiration system (AngioDynamics) provides a minimally invasive, endovas...

AngioDynamics (NASDAQ: ANGO) reported fiscal Q2 2026 results: net sales $79.4M (+8.8% pro forma) and Med Tech sales $35.7M (+13.0%). GAAP net loss was $6.4M (loss per share $0.15) and adjusted loss per share was $0.00. Adjusted EBITDA was $5.9M and cash was $41.6M.The company secured three regulatory milestones for its Mechanical Thrombectomy portfolio (APEX-Return IDE, PAVE IDE, modified AlphaVac 510(k)), concluded patent litigation with Bard, and raised FY2026 net sales guidance to $312–$314M and adjusted EBITDA to $8–$10M. CEO Jim Clemmer will retire upon successor appointment expected in fiscal 2027.

First patient enrolled in multi-center study evaluating innovative mechanical thrombectomy system across Europe, Canada, and Hong Kong. See trial details.

Clinical trial results reveal significant success for AngioDynamics' AlphaVac F1885 System in treating pulmonary embolism, with impressive clot reduction and safety profile.

Here are the top cardiovascular headlines from the past two weeks : Milestone readies mid February U.S. launch of Cardamyst, a home-use nasal spray for acute PSVT, with payer engagement and copay support. Allegheny Health Network opens Pennsylvania’s first South Asian Heart Clinic for prevention and risk stratification. AngioDynamics advances IDE programs and AlphaVac 510(k). Bayer’s asundexian cuts recurrent stroke without added major bleeding. AHA/ASA broaden AIS thrombolysis and EVT access. Abbott’s Amulet 360 shows closure. TricValve secures EU MDR certification. Brainomix adds automated net water uptake to its stroke AI.